Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
暂无分享,去创建一个
[1] E. Villablanca,et al. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? , 2022, Nature Reviews Gastroenterology & Hepatology.
[2] S. Vermeire,et al. Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All , 2022, Journal of Crohn's & colitis.
[3] S. Vermeire,et al. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises , 2022, Current research in pharmacology and drug discovery.
[4] Minhu Chen,et al. Precision medicine in IBD: genes, drugs, bugs and omics , 2021, Nature Reviews Gastroenterology & Hepatology.
[5] L. Joosten,et al. The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease , 2021, Journal of Crohn's & colitis.
[6] D. Plichta,et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. , 2021, Cell host & microbe.
[7] M. Dubinsky,et al. Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease. , 2021, Journal of Crohn's & colitis.
[8] D. Iliopoulos,et al. IBD Systems Biology Is Here to Stay. , 2021, Inflammatory bowel diseases.
[9] S. Ng,et al. Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. , 2021, Gastroenterology.
[10] A. Griffiths,et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.
[11] S. Vermeire,et al. Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis , 2020, Inflammatory bowel diseases.
[12] Chava L. Ramspek,et al. External validation of prognostic models: what, why, how, when and where? , 2020, Clinical kidney journal.
[13] M. Schloter,et al. Integrated microbiota and metabolite profiles link Crohn’s disease to sulfur metabolism , 2020, Nature Communications.
[14] Jack M. Fu,et al. Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD , 2020, Gut.
[15] P. Lanting,et al. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.
[16] L. Revilla Sancho,et al. Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis , 2020, medRxiv.
[17] M. Ferrante,et al. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. , 2020, The American journal of gastroenterology.
[18] Padhmanand Sudhakar,et al. Big data in IBD: big progress for clinical practice , 2020, Gut.
[19] D. Plichta,et al. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. , 2020, Inflammatory bowel diseases.
[20] M. Macoritto,et al. Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory Bowel Disease Colon Biopsies. , 2019, Inflammatory bowel diseases.
[21] M van Smeden,et al. Changing predictor measurement procedures affected the performance of prediction models in clinical examples. , 2019, Journal of clinical epidemiology.
[22] B. Alizadeh,et al. Nutritional Assessment in Inflammatory Bowel Disease (IBD)—Development of the Groningen IBD Nutritional Questionnaires (GINQ) , 2019, Nutrients.
[23] P. Rutgeerts,et al. Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. , 2019, Gastroenterology.
[24] G. D'Haens,et al. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review , 2019, Journal of Crohn's & colitis.
[25] D. Haller,et al. Multi-omics in IBD biomarker discovery: the missing links , 2019, Nature Reviews Gastroenterology & Hepatology.
[26] Kevin S. Bonham,et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases , 2019, Nature.
[27] Kenneth G. C. Smith,et al. A blood-based prognostic biomarker in IBD , 2019, Gut.
[28] J Jack Lee,et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.
[29] J. Stelling,et al. Microbial network disturbances in relapsing refractory Crohn’s disease , 2019, Nature Medicine.
[30] G. Collins,et al. PROBAST : A Tool to Assess the Risk of Bias and Applicability of PredictionModel Studies , 2018 .
[31] Kenneth G. C. Smith,et al. PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial , 2018, BMJ Open.
[32] C. Huttenhower,et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease , 2018, Nature Microbiology.
[33] J. Stoker,et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.
[34] B. Alizadeh,et al. Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ) , 2018, Journal of Gastroenterology.
[35] R. Xavier,et al. Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease. , 2018, Gastroenterology.
[36] Richard Hansen,et al. Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn’s disease , 2018, Microbiome.
[37] F. Baribaud. Molecular surrogates of histologic activity in Crohn′s disease , 2017 .
[38] D. Iliopoulos,et al. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy , 2017, Nature Reviews Gastroenterology & Hepatology.
[39] Huyuan Yang,et al. Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease , 2017, Journal of Crohn's & colitis.
[40] Richard D Riley,et al. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges , 2016, BMJ.
[41] L. Peyrin-Biroulet,et al. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease , 2016, Expert review of gastroenterology & hepatology.
[42] E. Seidman,et al. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease , 2016, Therapeutic advances in gastroenterology.
[43] H. Clevers,et al. Reparative inflammation takes charge of tissue regeneration , 2016, Nature.
[44] Gary S Collins,et al. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study , 2015, Statistics in medicine.
[45] G. D'Haens,et al. Assessment of mucosal healing in inflammatory bowel disease: review. , 2015, Gastrointestinal endoscopy.
[46] Karel G M Moons,et al. A new framework to enhance the interpretation of external validation studies of clinical prediction models. , 2015, Journal of clinical epidemiology.
[47] P. Austin,et al. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models , 2014, Statistical methods in medical research.
[48] A. Stensballe,et al. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. , 2014, World journal of gastroenterology.
[49] P. Rutgeerts,et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.
[50] Carme Camps,et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.
[51] Patrick Royston,et al. The cost of dichotomising continuous variables , 2006, BMJ : British Medical Journal.
[52] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[53] D. Iliopoulos,et al. Environmental triggers in IBD: a review of progress and evidence , 2018, Nature Reviews Gastroenterology & Hepatology.
[54] Valerii Fedorov,et al. Consequences of dichotomization , 2009, Pharmaceutical statistics.
[55] T. Ideker,et al. A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.